Myriad Genetics
MYGN • NASDAQ
Myriad Genetics is a medical - diagnostics & research company in the healthcare sector trading on NASDAQ, led by CEO Samraat S. Raha, with a market cap of $400.2M.
CEOSamraat S. Raha
Next Earnings
Upcoming earnings announcement for Myriad Genetics
Date
Tuesday, May 5, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.11
Revenue Estimate
$202.3M
Earnings History
Past 12 earnings reports for Myriad Genetics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | Q4 2025 | $0.04Est: -$0.05 | +180.0% | $209.8MEst: $207.6M | +1.1% |  10-K |
| Nov 3, 2025 | Q3 2025 | $0.00Est: -$0.05 | +100.0% | $205.7MEst: $205.2M | +0.3% | 10-Q |
| Aug 5, 2025 | Q2 2025 | $0.05Est: -$0.05 | +200.0% | $213.1MEst: $202.1M | +5.4% | 10-Q |
| May 6, 2025 | Q1 2025 | -$0.03Est: -$0.05 | +40.0% | $195.9MEst: $200.5M | -2.3% | 10-Q |
| Feb 24, 2025 | Q4 2024 | $0.03Est: $0.03 | 0.0% | $210.6MEst: $210.4M | +0.1% | 10-K |
| Nov 7, 2024 | Q3 2024 | $0.06Est: $0.02 | +200.0% | $213.3MEst: $210.7M | +1.2% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $0.05Est: -$0.01 | +600.0% | $211.5MEst: $205.0M | +3.2% | 10-Q |
| May 7, 2024 | Q1 2024 | -$0.01Est: -$0.10 | +90.0% | $202.2MEst: $193.3M | +4.6% | 10-Q |
| Feb 27, 2024 | Q4 2023 | $0.04Est: $0.01 | +300.0% | $196.6MEst: $194.8M | +0.9% | 10-K |
| Nov 6, 2023 | Q3 2023 | -$0.03Est: -$0.08 | +62.5% | $191.9MEst: $179.3M | +7.1% | — |
| Aug 3, 2023 | Q2 2023 | -$0.08Est: -$0.08 | 0.0% | $183.5MEst: $187.1M | -1.9% | 10-Q |
| May 3, 2023 | Q1 2023 | -$0.21Est: -$0.19 | -10.5% | $181.2MEst: $171.6M | +5.6% | — |